Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2022 16:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

COVALENT-111, a Phase I/II clinical trial in patients with type 2 diabetes, already underway in Canada, will now activate sites in the USAs previously reported, the Phase I portion of COVALENT-111 has...
December 12, 2022 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various tyrosine kinase domain...
November 11, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...
November 07, 2022 16:27 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights

Continued to establish Biomea Fusion as the next-generation leader in covalent medicinesExpanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered,...
November 03, 2022 09:19 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting

BMF-500, an investigational third generation covalent FLT3 inhibitor, has demonstrated preclinically that it may be the most potent and selective inhibitor of FLT3 evaluated to date: Greater...
October 31, 2022 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

BMF-219 is the first menin inhibitor to reach the clinic for type 2 diabetes. The Phase II portion of COVALENT-111 is designed to examine the capacity of BMF-219 to provide long-term glycemic control...
October 27, 2022 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

COVALENT-101 now includes patients with relapsed/refractory (R/R) CLLBMF-219 is the first menin inhibitor in the clinic for CLLPreclinical data presented at ASCO 2022 demonstrated the potency of...
October 14, 2022 09:00 ET | Source: Biomea Fusion, Inc.

BMF-219 Enters the Clinic for KRAS Solid Tumors

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.Biomea Fusion will now initiate a Phase I/Ib clinical...
September 22, 2022 09:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Treatment with BMF-219 led to an increase in beta cell mass in ex-vivo experiments with human donor isletsBMF-219 showed improved pancreatic beta-cell function and beta cell area, insulin sensitivity,...
September 20, 2022 07:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in a preclinical animal model, driving an...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right